SARASOTA, Fla., Sept. 30, 2004 (PRIMEZONE) -- The following is an investment opinion issued by eLocity Inc.:
Sciax Corp. (Pink Sheets:SCXC), Citrix Systems (Nasdaq:CTXS) and Immunomedics Inc. (Nasdaq:IMMU).
Small cap/special situation analyst Gil Oren of DBnewswire.com has initiated coverage of Sciax Corporation (Pink Sheets:SCXC). Sciax Corp. is an emerging leader in defense imaging systems for law enforcement and military personnel, engaged in counter-terrorism and other special security operations. Sciax Corp. reported on Monday after the closing bell on two more sales to BP Canada, a large oil and gas industry customer, for endoscope equipment used in the visual inspection of large reciprocating engines.
News on the Nasdaq;
Citrix Systems (Nasdaq:CTXS)
Rogers Wireless, Canada's leading provider of integrated wireless voice and data services, and Citrix Systems, the global leader in access infrastructure solutions, announced Wednesday a new relationship under which the two companies will jointly offer organizations wide area, wireless access solutions over the Rogers Wireless EDGE network in Canada.
The companies announced that the Rogers Wireless Enhanced Data rates for Global Evolution network and the Citrix MetaFrame Access Suite provided mobile workers secure, easy and instant access to enterprise applications and information from anywhere and at anytime. The companies added that the MetaFrame customers would be able to access ERP, inventory status, order entry, sales force automation, CRM and other such full-featured business applications with this collective offering.
The companies said that the business benefits from the joint offering included lower operating costs, greater productivity, faster time-to-market and increased customer satisfaction, and that the joint go-to-market solutions would enable companies to use the Citrix MetaFrame in a wireless environment.
CTXS closed Wednesday up $0.84 at $17.62 on volume of 1,918,087 shares.
Immunomedics Inc. (Nasdaq:IMMU)
Biopharmaceutical company Immunomedics Inc. announced Wednesday settlement of its patent infringement suit against Cytogen Corp. and C.R. Bard Inc. for an undisclosed payment and without any admission of fault or liability.
Immunomedics had alleged that Cytogen's ProstaScint product infringed upon one of Immunomedics' key patents for detecting cancerous tumors. Cytogen's ProstaScint is used to detect prostate cancer.
IMMU ended Wednesday's trading session higher by 0.31 at $2.71, 12.92 percent, on above average volume.
About eLocity Inc: eLocity owns and operates three financial websites for investors.
-PennyPicks.com, http://www.pennypicks.com/. Featuring active message boards for the penny stock trader, rumors and more.
-StockGrid.com, http://www.stockgrid.com/. Visit this site for our daily top stock "GRID Makers". We rank stocks on volume, message board activity, sentiment and trend forecast.
-Bell2Bell.com, http://www.bell2bell.com/. Bell2Bell features news stories, rumors, the InvestBoard and more.
Sign up for FREE at any of the sites above.
The newsletter is provided by eLocity Inc., an electronic broadcaster and publisher of this newsletter, here after referred to as "the company". The company received compensation for this newsletter service for Sciax Corp. (public company). The compensation is fifteen thousand dollars from a non-affiliated third party, Alex Consulting Inc. Because the company is receiving compensation for its services, there is an inherent conflict of interest in the company statements and opinions and such statements and opinions cannot be considered independent.
The company reserves the right to trade in securities mentioned herein, and may make purchases or sales in such securities featured within our newsletter reports. The information contained in this publication is for informational purposes only, and not to be construed as an offer to sell or solicitation of an offer to buy any security. The company makes no representation or warranty relating to the validity of the facts presented nor does the company represent or warrant that all material facts necessary to make an investment decision are presented above. All statements of opinions, if any, (Our Summary) are those of the company.
The company relies exclusively on information gathered on the public company, such as public filings, press releases and its web sites. Investors should use the information contained in this publication as a starting point for conducting additional research on the public company in order to allow the investor to form his or her own opinion regarding the public company. Factual statements contained in this publication are made as of the date stated and they are subject to change without notice. The company is not a registered investment adviser, broker or a dealer.
Investing in the public company that this newsletter is providing service for should be reviewed is speculative and a high-risk and may result in the loss of some or all of any investment made in the client. This release may contain statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended.
The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend," and similar expressions and variations thereof are intended to identify forward-looking statements.